GlobeNewswire by notified

Intertrust announces EUR 100 million share buyback programme

Share

Amsterdam, the Netherlands – 27 September 2021 – Intertrust N.V. (“Intertrust” or “the Company”) [Euronext: INTER], a global leader in providing tech-enabled fund and corporate solutions, today announces a programme to repurchase ordinary shares in its capital for a total aggregate consideration of EUR 100 million. This decision is part of a process undertaken over recent months in which Intertrust’s Management Board and Supervisory Board have explored, and continue to actively explore, a number of options to maximize shareholder value. The Boards are of the view that the current market valuation of the Company does not accurately reflect its intrinsic value.

Share buyback programme
The Intertrust Management Board and Supervisory Board firmly believe in the strategy that has seen the Company consolidate its focus on high-growth areas, and are confident to deliver long-term shareholder value. To demonstrate its confidence in the Company’s long-term prospects and reflecting the strong cash generation, whilst maintaining financial flexibility, Intertrust is committing to acquire up to approximately 8.2 million shares, based on the recent closing price on Euronext Amsterdam.

Shankar Iyer (CEO), said: “Today we announce a 100 million euro buyback programme, in recognition of the need to drive shareholder returns while maintaining focus on long-term value creation. We have a clear strategy on which we are delivering, and we are confident that it will create value for all stakeholders. We therefore see no better investment at this moment in time than in the shares of our own company, which we view as undervalued in light of our clear long-term potential. We continue to consider options to drive value for all our stakeholders and look forward to providing a comprehensive update on our strategy to shareholders on our capital markets day on 23 November.”

The share repurchase will be funded from Intertrust’s available cash resources while delivering on our stated commitment to reduce leverage. The Intertrust management team remains fully focused on delivering the Company’s current strategy and will continue to invest in the business to drive organic growth, including capex investments at around 3% of revenue.

Intertrust has engaged an independent broker to execute the repurchase transactions on its behalf. The ordinary shares are being repurchased at a price that does not exceed the lower of (1) a maximum of 110% of the average of the highest quoted price per share on the last five consecutive trading days immediately preceding the date of repurchase, according to the Official Price List of Euronext Amsterdam and (2) the threshold stipulated by Article 3(2) of Commission Delegated Regulation (EU) 2016/1052. The share repurchase will be funded from Intertrust’s available cash resources.

A portion of the repurchased shares will be used for existing employee stock ownership plans which will vest in 2022, 2023 and 2024. The remainder of the repurchased shares are intended to be cancelled after approval by the general meeting of shareholders.

The share buyback programme will be implemented within the limitations of the authority granted to the Management Board by the Annual General Meeting of Shareholders, which authorised the Management Board to purchase up to 10% of Intertrust's issued share capital per 14 May 2021, for a period of 18 months starting 14 May 2021 and ending 14 November 2022. The Supervisory Board has approved the share buyback programme on 26 September 2021. If and to the extent required, further shareholders’ approval will be requested as referred to in Section 2:98 paragraph 4 of the Dutch Civil Code. The share repurchase programme will be conducted in accordance with the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 and within the safe harbour parameters for repurchase programmes.

Further details and weekly updates of the progress of this share repurchase programme and the information will also be available on Intertrust’s Investor Relations website intertrustgroup.com/investors.

This press release contains information which is to be made publicly available under the Market Abuse Regulation (EU) No 596/2014.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nokia Corporation: Repurchase of own shares on 28.03.202428.3.2024 21:30:00 CET | Press release

Nokia Corporation Stock Exchange Release 28 March 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 28.03.2024 Espoo, Finland – On 28 March 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL467,1243.29CEUX--BATE--AQEU--TQEX--Total467,1243.29 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 202328.3.2024 21:28:47 CET | Press release

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We are laser focused on executing the PRESent registrational studies for SerpinPC, a potential first-in-class subcutaneously administered therapy with a differentiated safety profile for individuals with he

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results28.3.2024 21:05:00 CET | Press release

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, “I’m pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin against the backdrop of significant cost cutting initiatives undertaken to align our operating structure with our strategic vision for growth. We believe that our rapid and flexible mRNA synthesis kits are game-changing and unlock tremendous value by providing customers control over their screening and d

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings28.3.2024 21:01:00 CET | Press release

Publication of annual report for financial year 2023Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders’ Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company. The annual report for the financial year 2023, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. Our annual 2023 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the

McWhorter Foundation Preparing Legal Battle Against J.P. Morgan Over IPO Discrimination and LBO Biases28.3.2024 19:28:47 CET | Press release

PALM BEACH, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- McWhorter Foundation is poised to launch a groundbreaking legal battle against financial giant J.P. Morgan. With a focus on challenging discriminatory practices in leveraged buyouts (LBOs) and initial public offerings (IPOs), The McWhorter Foundation aims to break down barriers and advocate for equal access to capital markets. Exposing Inequities in IPOs: Recent analyses have highlighted disparities in IPO access, with minority-owned businesses facing systemic hurdles in accessing public markets. McWhorter's legal challenge will illuminate these inequities, compelling J.P. Morgan to address its role in perpetuating barriers to entry for underrepresented entrepreneurs. Leveraging Data for Change: Backed by comprehensive data and extensive research, McWhorter's legal team will present compelling evidence of discrimination in J.P. Morgan's IPO practices. By highlighting patterns of exclusion and unequal treatment, McWhorter Foundation s

HiddenA line styled icon from Orion Icon Library.Eye